share_log

復宏漢霖:自願公告 - 地舒單抗生物類似藥HLX14(重組抗RANKL全人單克隆抗體注射液)用於治療骨折高風險的絕經後婦女的骨質疏鬆症的國際多中心3期臨床研究達到主要研究終點

HENLIUS: VOLUNTARY ANNOUNCEMENT - AN INTERNATIONAL MULTI-CENTRE PHASE 3 CLINICAL STUDY OF A BIOSIMILAR OF DENOSUMAB HLX14 (RECOMBINANT ANTI-RANKL HUMAN MONOCLONAL ANTIBODY INJECTION) FOR THE TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN AT HIGH RISK FO

香港交易所 ·  Apr 5 06:00
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more